Jackson Creek Investment Advisors LLC Decreases Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jackson Creek Investment Advisors LLC lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 59.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 29,284 shares of the biopharmaceutical company's stock after selling 42,465 shares during the period. Jackson Creek Investment Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $710,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CPRX. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after buying an additional 390,116 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Catalyst Pharmaceuticals by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company's stock worth $56,477,000 after buying an additional 180,100 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth $37,494,000. Bank of America Corp DE boosted its stake in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock worth $32,741,000 after buying an additional 913,843 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Catalyst Pharmaceuticals by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock worth $31,379,000 after buying an additional 119,766 shares during the last quarter. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,630,912.64. This trade represents a 74.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the sale, the insider directly owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock worth $5,879,369 in the last quarter. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Down 2.0%

Shares of CPRX traded down $0.42 during mid-day trading on Friday, reaching $21.03. The company had a trading volume of 1,230,712 shares, compared to its average volume of 1,146,224. Catalyst Pharmaceuticals, Inc. has a 52-week low of $15.34 and a 52-week high of $26.58. The stock has a market capitalization of $2.57 billion, a P/E ratio of 13.39, a PEG ratio of 0.86 and a beta of 0.66. The stock has a 50 day moving average of $23.23 and a two-hundred day moving average of $22.89.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $32.83.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.